- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06308705
The SsRI/NIE Recombinant Antigen ELISA for the Follow up of Patients Infected by Strongyloides Stercoralis
This is a single-center interventional study with an IVD medical device.
The main objective of this study is to evaluate the ELISA SsIR/NIE test for the post-treatment follow-up of patients suffering from strongyloidosis, using well-characterized sera from a previous study.
All sera available in the Tropica biobank and coming from the Strong Treat study, for which serum samples collected at baseline and at 12-month follow-up are available, will be eligible for the study.
The test The InBios Strongy Detect TM IgG ELISA detects specific IgG antibodies against recombinant Strongyloides NIE and SsIR antigens in serum. It consists of an enzymatically amplified sandwich immunoassay. Positive and negative control samples are provided in the kit. The test will be performed and interpreted according to the manufacturer's instructions. The results are expressed as OD and nOD. Clinical interpretation of the results will be performed by receiver operating characteristic (ROC) curve analysis generated using data from confirmed positive and confirmed negative samples.
The laboratory technicians will receive from the PI of the study a list of pseudo-anonymized sera to be tested with SsIR/NIE ELISA, they will check their availability and proceed with the test according to the Manufacturer's instructions. Laboratory personnel performing and reading the tests will be blinded to the results of any previously performed tests (and the classification of the sample in the Strong Treat study). A single run will be performed for each sample, unless the test needs to be repeated due to any technical problem. Both baseline and follow-up sera will be tested. The resulting OD and nOD will be reported in an Excel file by the laboratory technicians performing the tests.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Verona
-
Negrar, Verona, Italy, 37024
- IRCCS Sacro Cuore Don Calabria hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All sera available in our biobank and originating from the Strong Treat trial
- availability of the baseline and the 12-month follow up serum of each included case
Exclusion Criteria:
- unavailability of the baseline or of the 12-month follow up serum of each included case
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Sera
All sera available in our biobank and originating from the Strong Treat trial will be eligible for the study, based on the availability of the baseline and the 12-month follow up serum of each included case.
|
The InBios Strongy Detect TM IgG ELISA detects specific IgG antibodies to Strongyloides recombinant antigens NIE and SsIR in serum.
It consists of an enzymatically amplified sandwich-type immunoassay.
Positive and negative control samples are provided in the kit.
The test will be run and interpreted according to the manufacturer's instruction.
The results are expressed as OD and nOD.
Clinical interpretation of the results will be done by analysis of the Receiver Operating Characteristics (ROC) curve generated using data from confirmed positive and confirmed negative samples.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Result of the SsIR/NIE ELISA
Time Frame: Baseline and at the 12-month follow-up
|
For each sample, the result of the SsIR/NIE ELISA will be compared with the outcome category (cure/persistence of infection) defined at the 12-month follow up within the Strong Treat study.
Similarly to what is established with other serology tests, SsIR/NIE ELISA will indicate parasitological cure when at least a twofold reduction of nOD at the 12-month follow up, compared to the baseline nOD, will be observed.
|
Baseline and at the 12-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion
Time Frame: Baseline and at the 12-month follow-up
|
Proportion of SsIR/NIE ELISA tests showing complete seroreversion within the subgroup of cases that will be correctly (in comparison with the Strong Treat category) classified as cured by the SsIR/NIE ELISA.
|
Baseline and at the 12-month follow-up
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Strongyloides Stercoralis Infection
-
Jennifer KeiserNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; National Institute of Public Health, Vientiane, LaosEnrolling by invitationStrongyloides Stercoralis InfectionCambodia, Lao People's Democratic Republic
-
Jennifer KeiserNational Centre for Parasitology, Entomology and Malaria Control, CambodiaCompletedStrongyloides Stercoralis InfectionCambodia
-
Swiss Tropical & Public Health InstituteNational Institute of Public Health, Vientiane, LaosNot yet recruitingStrongyloidiasis | Strongyloides Stercoralis Infection
-
Universidad Nacional de SaltaAlbert B. Sabin Vaccine Institute; Fundacion Mundo SanoUnknownHelminthiasis | Strongyloides Stercoralis InfectionArgentina
-
Albert Einstein College of MedicineTerminatedStrongyloidiasis | Strongyloides Stercoralis InfectionUnited States
-
IRCCS Sacro Cuore Don Calabria di NegrarWorld Health Organization; Universidad Central del Ecuador; CECOMET (Centro de...CompletedStrongyloidiasis | Strongyloides Stercoralis InfectionEcuador
-
IRCCS Sacro Cuore Don Calabria di NegrarNot yet recruitingStrongyloides Stercoralis InfectionItaly
-
National Institute of Allergy and Infectious Diseases...RecruitingMalaria | Intestinal Worms | GI Protozoa | Echiniococcus | StrongyloidesUnited States
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
Clinical Trials on InBios Strongy Detect TM IgG ELISA
-
IRCCS Sacro Cuore Don Calabria di NegrarWorld Health Organization; Universidad Central del Ecuador; CECOMET (Centro de...CompletedStrongyloidiasis | Strongyloides Stercoralis InfectionEcuador